



NEWS RELEASE

April 7, 2025

Company name: TMS Co., Ltd.
Name of representative: Takuro Wakabayashi, Chief Executive Officer
(Securities code: 4891; Growth Market)

Notice of TMS-008 Phase I First Data Readout

TMS Co., Ltd. (TSE: 4891) (the "Company"), a clinical-stage biopharmaceutical company focused on discovering and accelerating the development of transformative medicines in areas of high unmet medical need, is pleased to announce that the Company had the first data readout of TMS-008 Phase I clinical trial (the "Study") and TMS-008 demonstrated good safety and tolerability.

The Study is the First-In-Human study of TMS-008 in which the drug candidate was administered to human subjects for the first time. In this Study, TMS-008 was administered to healthy adult male subjects in escalating doses (five cohorts) to confirm safety, tolerability, and pharmacokinetics in humans. At the first data readout, good safety and tolerability were demonstrated in all the five cohorts. Pharmacokinetics goals were also met.

An overview of the Study can be found on the jRCT (Japan Registry of Clinical Trials)* website.

*In Japanese

URL: <https://jrct.mhlw.go.jp/latest-detail/jRCT2031240084>

About TMS-008

TMS-008 is a compound of SMTP (Stachybotrys microspora triprenyl phenol) family compounds derived from a type of black mold. The compound has strong anti-inflammatory and antioxidant activity by inhibiting soluble epoxide hydrolase (sEH) and is expected to have potential as a treatment for acute kidney injury.

This event will have no impact on the Company's financial results for the current fiscal year, while it is expected to contribute to improvement of the Company's mid-to long-term business performance.

TMS Co., Ltd.

TMS Co., Ltd. is a clinical-stage biopharmaceutical company focused on the discovery and development of transformative medicines for the treatment of serious diseases in areas of high unmet medical need. The Company's pipeline consists of a family of small molecule compounds called SMTPs (*Stachybotrys microspora* triprenyl phenols) derived from a fungus. TMS' lead program, TMS-007 (JX10), has demonstrated efficacy and safety in its Phase 2a study for the treatment of acute ischemic stroke. The Company's robust pipeline also includes programs in resistant or uncontrolled hypertension, acute kidney injury, and spinal cord injury. TMS continues to explore new pipeline products by leveraging its established partnerships with leading academic institutions in Japan, with the intention to build a bridge between academic discoveries and the global pharmaceutical market. For more information about TMS, please visit <https://www.tms-japan.co.jp/>.

Investor and Media Contact:
ir@tms-japan.co.jp

End